NIPT

Noninvasive Prenatal Testing
When You’re Expecting

Safe Genetic Screening

All pregnancies have a small chance for a genetic disorder, regardless of maternal age, family history or personal health. Noninvasive prenatal testing (NIPT) is a new method of testing which looks at the DNA from your baby’s placenta. More accurate and completely safe for you and your baby, NIPT might help you avoid the need for more invasive tests during your pregnancy.

Finding out if your baby has a potential condition can certainly be scary. However, determining risks early on with NIPT can help you and your doctor decide the next best steps, including if you need further testing, and how to plan for your baby’s special health needs.

How does Noninvasive Prenatal Testing work?

DNA from the pregnancy can naturally be found in your blood during pregnancy. With a simple blood sample, an NIPT test can analyze the DNA — the substance that makes up our chromosomes and holds all of our genetic information — from the placenta found in your blood. This can help to identify the risk that your baby might be affected by a chromosomal condition. Your doctor may recommend additional types of testing if you have a positive NIPT result.

Placental Fetal DNA

Noninvasive prental testing can be performed from 10 weeks of pregenacy

Mother’s Bloodstream

Small fragments of DNA from the pregnancy circulate

Mother’s Blood Sample

Pregnancy DNA is analyzed from a simple blood sample

How are results interpreted?

Low Risk

A low risk result indicates that your baby is unlikely to be affected by any of the screened chromosomal conditions.

Increased Risk

An increased risk result indicates a high chance that your baby has a disorder. Your doctor may suggest more testing to confirm the result.

Inconclusive Result

Sometimes a result cannot be obtained for a variety of reasons. In these cases, we encourage you to have a discussion with your doctor to decide next steps.

Vanadis® NIPT

The Vanadis NIPT system is the next-generation of noninvasive prenatal testing. Thanks to technological breakthroughs, the Vanadis NIPT solution helps provide more accurate results faster — results are usually available within one week — and its design reduces the complexity and cost of noninvasive prenatal testing, making it accessible to more women. Any pregnant woman who wants to know if her baby is at risk for one of the common chromosomal conditions can be screened using the Vanadis NIPT system.

What conditions can the Vanadis NIPT solution identify?

Vanadis routinely screens for conditions such as Down (trisomy 21), Edwards (trisomy 18), and Patau (trisomy 13) syndromes. Screening for fetal sex may also be included (if allowed by country-specific legislation).

When can the test be performed?

A NIPT test can be performed on the Vanadis NIPT platform after 10 weeks of pregnancy. This timing ensures that there is enough of the baby’s DNA present in the maternal blood sample to be properly analyzed.

Where can I get NIPT performed using the Vanadis NIPT system?

Various clinical laboratories have installed the Vanadis NIPT platform to be able to offer reliable and cost-effective noninvasive prenatal testing. For more information, ask your healthcare provider about Vanadis NIPT, or contact us.

FAQs

Read our Frequently Asked Questions about’ NIPT.

FAQs

Read FAQs

Talk to your doctor about Noninvasive Prenatal Testing

Contact your doctor about the prenatal screening and diagnostic tests that are available to you – they may vary by country.

Other Screening Solutions

Parents - Pre-Eclampsia

Learn More

Parents - Newborn Screening

Learn More

References

McCullough et al. Non-Invasive Prenatal Chromosomal Aneuploidy Testing – Clinical Experience: 100,000 Clinical Samples. (2014) PLoS ONE 9 (10): e109173.

Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231–237

Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of Cell-Free DNA in Maternal Blood in Screening For Aneuploidies: Updated Meta-Analysis. Ultrasound Obstet Gynecol 2017 Sep;50(3):302-314. DOI: 10.1002/uog.17484

https://www.nhs.uk/conditions/amniocentesis/risks/

Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F. Ultrasound Obstet Gynecol. 2015 Jan;45(1):16-26. doi: 10.1002/uog.14636.

Gregg et al. Non-invasive prenatal screening for fetal aneuploidy: 2016 update. Genet Med. (2016) doi:10.1038/gim.2016.97

Disclaimer

PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.